| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA288690
Max Phase: Preclinical
Molecular Formula: C18H38N6O9
Molecular Weight: 482.54
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: NCC1OC(OC2C(N)CC(N)C(OC3OC(CN)C(O)C(O)C3N)C2O)C(O)C(N)C1O
Standard InChI: InChI=1S/C18H38N6O9/c19-2-6-10(25)8(23)13(28)18(31-6)33-16-5(22)1-4(21)15(14(16)29)32-17-9(24)12(27)11(26)7(3-20)30-17/h4-18,25-29H,1-3,19-24H2
Standard InChI Key: CPWPAIPMEJQEDV-UHFFFAOYSA-N
Associated Targets(non-human)
Lysosomal phospholipase A1 40 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 482.54 | Molecular Weight (Monoisotopic): 482.2700 | AlogP: -7.36 | #Rotatable Bonds: 6 |
| Polar Surface Area: 294.19 | Molecular Species: BASE | HBA: 15 | HBD: 11 |
| #RO5 Violations: 2 | HBA (Lipinski): 15 | HBD (Lipinski): 17 | #RO5 Violations (Lipinski): 2 |
| CX Acidic pKa: 12.40 | CX Basic pKa: 9.68 | CX LogP: -7.27 | CX LogD: -15.18 |
| Aromatic Rings: 0 | Heavy Atoms: 33 | QED Weighted: 0.17 | Np Likeness Score: 1.17 |
References
| 1. Mingeot-Leclercq MP, Van Schepdael A, Brasseur R, Busson R, Vanderhaeghe HJ, Claes PJ, Tulkens PM.. (1991) New derivatives of kanamycin B obtained by modifications and substitutions in position 6''. 2. In vitro and computer-aided toxicological evaluation with respect to interactions with phosphatidylinositol., 34 (4): [PMID:2016725] [10.1021/jm00108a036] |
Source
Source(1):